Glaxosmithkline

GlaxoSmithKline (GSK), a pharmaceutical preparation manufacturer headquartered in Great Britain, has demonstrated a commitment to reducing its carbon emissions.

Emissions Data:

• 2024: GSK reported a total of approximately 8.9 billion kg CO2e (Scope 1, 2, and 3 emissions). This included approximately 521 million kg CO2e for Scope 1 emissions and approximately 44 million kg CO2e for Scope 2 (market-based) emissions. Scope 3 emissions were approximately 8.38 billion kg CO2e, with purchased goods and services accounting for about 2.83 billion kg CO2e.
• 2023: Total emissions were approximately 9.56 billion kg CO2e. Scope 1 emissions were around 580 million kg CO2e, and Scope 2 (market-based) emissions were approximately 64 million kg CO2e. Scope 3 emissions totalled about 8.98 billion kg CO2e, with purchased goods and services being the largest contributor at approximately 2.98 billion kg CO2e.
• 2022: Total emissions amounted to approximately 9.62 billion kg CO2e. Scope 1 emissions were approximately 626 million kg CO2e, and Scope 2 (market-based) emissions were around 88 million kg CO2e. Scope 3 emissions were approximately 8.99 billion kg CO2e.
• 2021: Total emissions were approximately 9.39 billion kg CO2e. Scope 1 emissions were approximately 633 million kg CO2e, and Scope 2 (market-based) emissions were around 131 million kg CO2e. Scope 3 emissions totalled approximately 8.62 billion kg CO2e.
• 2020: Total emissions were approximately 10.72 billion kg CO2e. Scope 1 emissions were about 711 million kg CO2e, and Scope 2 (market-based) emissions were approximately 169 million kg CO2e. Scope 3 emissions were around 9.95 billion kg CO2e.

Climate Commitments and Reduction Targets:

GSK has set ambitious targets to achieve net-zero greenhouse gas emissions across its full value chain.

• Net Zero by 2045: GSK has committed to achieving net-zero greenhouse gas emissions across its entire value chain by 2045, based on a 2020 baseline. This involves an absolute reduction of at least 90% in emissions, with any remaining emissions being neutralised through high-quality carbon credits. This target is aligned with the Science Based Targets initiative (SBTi) Net Zero Standard.
• Near-Term Targets (by 2030):
  • A commitment to an 80% reduction in absolute Scope 1 and 2 GHG emissions by 2030 from a 2020 base year.
  • An 80% reduction in absolute Scope 3 GHG emissions (covering purchased goods and services, fuel and energy related activities, upstream transportation and distribution, waste generated in operations, business travel, employee commuting, use of sold products, and end-of-life treatment of sold products) by 2030 from a 2020 base year.
• Earlier Targets: GSK previously committed to reducing Scope 1 and 2 GHG emissions by 34% by 2025 from a 2017 baseline, and Scope 3 GHG emissions by 16% by 2030 from a 2017 base year, as validated by the SBTi.
• Operational Emissions Reduction: In 2021, the company reported a 15% reduction in Scope 1 and 2 carbon emissions compared to 2020.

GSK's emissions data and commitments are sourced directly from the company's reporting and are not cascaded from a parent organisation.